文献速递前列腺癌

男性饮食与生活方式(MEAL)研究(CALGB 70807[Alliance]):前列腺癌主动监测男性饮食随机试验的招募可行性与基线人口学特征

Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer.
PubMed 文献 · BJU Int · 2017-05-21

MEAL研究(CALGB 70807[Alliance])是一项III期临床试验,评估高蔬菜饮食能否预防主动监测(AS)前列腺癌患者的疾病进展。2011至2015年间在91个研究中心随机化478例(目标的103%),基线平均年龄64岁、平均PSA 4.9 ng/mL,组间各基线特征无显著差异;前50例活检中央病理复核仅1例(2%)不符合入选标准。

要点

  • 在91个研究中心随机化478例,达到目标464例的103%,显示全国多中心III期饮食干预试验可行。
  • 基线平均年龄64岁、平均PSA 4.9 ng/mL,组间年龄、种族、PSA、临床分期及Gleason评分均无显著差异。
  • 前50例基线前列腺活检经中央病理复核,1例(2%)不符合入选标准。

核心结论

  • MEAL研究表明,开展全国性、多中心III期前列腺癌饮食干预临床试验是可行的,也表明在主动监测人群中测试预防疾病进展的干预措施是可行的。

研究设计与样本

  • MEAL研究(CALGB 70807[Alliance])是一项III期临床试验,测试高蔬菜饮食对主动监测前列腺癌患者预防疾病进展的疗效。
  • 参与者被随机分配到经过验证的饮食咨询干预组或对照组。
  • 采用卡方检验和Kruskal-Wallis分析评估基线时组间差异。

主要发现

  • 2011年至2015年间,在91个研究中心随机化478例(目标的103%),目标样本量为464例。
  • 基线平均(标准差)年龄为64(6)岁,平均(标准差)PSA浓度为4.9(2.1)ng/mL。
  • 56例(12%)参与者为非洲裔美国人,17例(4%)为西班牙裔/拉丁裔,16例(3%)为亚裔美国人。
  • 组间在年龄(P=0.98)、种族/民族(P=0.52)、地理区域(P=0.60)、前列腺癌诊断后时间(P=0.85)、PSA浓度(P=0.96)、临床分期(T1c或T2a;P=0.27)及Gleason评分(Gleason 6或3+4=7;P=0.76)方面均无显著差异。
  • 在预先计划的分析中,前50例参与者的基线前列腺活检样本接受中央病理复核以确认入选资格,预期<10%将不符合入选标准;50例中1例(2%)不符合入选标准。

关键数值与推荐

  • 临床试验方案将参与者随机分配至高蔬菜饮食咨询干预组或对照组,不涉及其他干预阈值。
  • 入组标准涉及临床分期T1c或T2a及Gleason评分6或3+4=7,原文未报告具体阈值或其他入选标准。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. METHODS: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi-squared and Kruskal-Wallis analyses were used to assess between-group differences at baseline. RESULTS: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian-American. There were no significant between-group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. CONCLUSION: The MEAL study shows the feasibility of implementing national, multi-institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Parsons JK, Pierce JP, Mohler J, et al. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int. 2017. PMID: 28437029. doi:10.1111/bju.13890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。